Axonics Modulation Technologies (NASDAQ: AXNX) reported Q3 EPS of ($0.24), $0.26 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $35.2 million versus the consensus estimate of $22.95 million.

Raymond W. Cohen, CEO of Axonics, said, \"In the third quarter, despite headwinds from COVID-19 and the launch of a rechargeable device by our competitor, we continued to add new customers, sign additional hospital system agreements, gain regulatory approvals, and expand our growing body of clinical literature. Our strong revenue results reflect the close working relationships we have developed with implanting physicians, the successful launch of our second-generation implantable neurostimulator, and most importantly, the high satisfaction rates being reported by patients since our U.S. launch a year ago. It is our conviction that the SNM market is poised for significant market expansion and given the quality of our team and product pipeline, we are confident that Axonics is well positioned for continued growth in the years ahead.”

For earnings history and earnings-related data on Axonics Modulation Technologies (AXNX) click here.